Analyzing Supernus Pharmaceuticals (SUPN) and Its Competitors
Supernus Pharmaceuticals (NASDAQ: SUPN) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Supernus Pharmaceuticals to similar businesses based on the strength of its risk, earnings, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Valuation & Earnings
This table compares Supernus Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Supernus Pharmaceuticals||$252.59 million||$82.36 million||21.05|
|Supernus Pharmaceuticals Competitors||$2.57 billion||$977.16 million||-0.32|
Supernus Pharmaceuticals’ rivals have higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Supernus Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Supernus Pharmaceuticals Competitors||-540.60%||-41.61%||-24.68%|
Volatility and Risk
Supernus Pharmaceuticals has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals’ rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
Insider & Institutional Ownership
95.4% of Supernus Pharmaceuticals shares are held by institutional investors. Comparatively, 66.8% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 6.7% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 11.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations for Supernus Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Supernus Pharmaceuticals Competitors||66||307||951||27||2.70|
Supernus Pharmaceuticals currently has a consensus price target of $47.50, suggesting a potential upside of 15.71%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 24.46%. Given Supernus Pharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Supernus Pharmaceuticals has less favorable growth aspects than its rivals.
Supernus Pharmaceuticals rivals beat Supernus Pharmaceuticals on 7 of the 13 factors compared.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.